advertisement

WGA Rescources

Kunimatsu-Sanuki S 10

Showing records 1 to 10 | Display all abstracts from Kunimatsu-Sanuki S

100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Inoue K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Inoue K
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Shiokawa M
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Shiokawa M; Katakura S
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Kunimatsu-Sanuki S; Nozaki N
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tsuruoka M; Kunimatsu-Sanuki S
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Shimizu K; Ishida K
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Shimizu K; Ishida K
American Journal of Ophthalmology 2022; 237: 114-121
100698 One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
Tomita G
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 354-358
99683 Periocular Adverse Reactions to Omidenepag Isopropyl
Tomita G
American Journal of Ophthalmology 2022; 237: 114-121

Issue 23-1

Change Issue


advertisement

Nidek